Physical and Chemical Barriers to Infection

Physical and chemical barriers are the body's first line of defense: constitutive, non-inducible mechanisms that exist at all times, independent of prior exposure to any specific pathogen. They are distinguished from the rest of innate immunity — phagocytes, complement, natural killer cells, inflammation — by one key feature: barriers act to prevent entry, whereas the cellular innate system acts to eliminate microbes that have already entered. This distinction matters because barrier failure (a wound, a burn, a genetic defect in mucus clearance) is the single most common cause of infection, and most infectious disease starts as a breach of a barrier rather than a failure of cellular immunity. Three categories of barrier operate together at every body surface exposed to the environment: skin, respiratory tract, gastrointestinal tract, and urogenital tract.

• Physical/mechanical barriers: an unbroken layer of tightly connected epithelial cells, reinforced by structural features (keratin, tight junctions, cilia, peristalsis, urine flow, tears, coughing/sneezing) that either block microbes outright or physically sweep them away.
• Chemical barriers: secreted or surface-associated molecules that are directly microbicidal or microbistatic — gastric acid, skin sebum fatty acids, lysozyme, antimicrobial peptides (defensins, cathelicidins), and low pH in the vagina and stomach.
• Microbiological barriers: the resident microbiota, which occupies epithelial attachment sites, consumes available nutrients, and produces bacteriocins and organic acids that suppress invading species — a phenomenon called colonization resistance.

A useful conceptual anchor from Overview of the Immune System: Innate vs Adaptive is that innate immunity trades specificity for speed: barriers are maximally fast (already present, no lag time) but recognize nothing at the molecular level — they simply make the local environment uninhabitable or impassable for essentially any microorganism, pathogen or not.

Skin: a physical fortress built by dying cells. The epidermis is a stratified squamous epithelium renewed continuously from a basal stem cell layer. As keratinocytes divide and are pushed upward, they undergo a programmed process of terminal differentiation: they flatten, extrude their organelles, and fill with the fibrous protein keratin, finally dying to form the stratum corneum — a layer of dead, keratin-packed corneocytes cemented together by lipids (ceramides, cholesterol, free fatty acids) into a "brick and mortar" structure. This layer is water-impermeable, mechanically tough, and takes roughly 2–4 weeks to turnover completely, continuously shedding surface cells (and any microbes attached to them) via desquamation. Living epidermal keratinocytes are joined by tight junctions and desmosomes, sealing the paracellular space so that bacteria cannot simply squeeze between cells. Sebaceous glands secrete sebum, whose free fatty acids and lactic acid keep skin pH around 4.5–6.0 (mildly acidic — the "acid mantle"), inhibiting most bacteria and fungi while tolerating lipophilic commensals such as Cutibacterium acnes.

Mucosal epithelia: barriers that must also permit exchange. The respiratory, gastrointestinal, and urogenital tracts cannot be sealed like skin because they need to exchange gases, absorb nutrients, and pass fluids. Instead, they rely on a single or few-layered epithelium covered by a mucus gel, a viscous mixture of water and heavily glycosylated mucin glycoproteins (e.g., MUC5AC, MUC5B in airways; MUC2 in the gut) that traps microbes physically and prevents them from reaching the epithelial cell surface to adhere. In the airway, ciliated epithelial cells beat mucus continuously upward toward the pharynx at roughly 1 cm/min, a conveyor system called the mucociliary escalator; trapped particles and microbes are swallowed or expectorated. Coughing and sneezing are reflex accelerants of this same clearance mechanism. In the gut, the mucus layer is bilaminar in the colon — a dense, largely sterile inner layer adherent to the epithelium and a looser outer layer that the microbiota is permitted to colonize — and peristalsis physically flushes contents (and organisms) forward, discouraging bacterial overgrowth in the small intestine. In the eye, continuous tear flow, blinking, and lysozyme-rich secretions wash the ocular surface; in the urinary tract, unidirectional urine flow mechanically prevents ascending colonization.

Chemical hostility: pH, enzymes, and antimicrobial peptides. Several chemical environments are lethal to most microbes by design:

Lysozyme (discovered in nasal mucus and tears, described below) is a small enzyme that hydrolyzes the β-1,4 glycosidic bond between N-acetylmuramic acid and N-acetylglucosamine in bacterial peptidoglycan, catastrophically weakening the cell wall of Gram-positive bacteria (Gram-negative bacteria are more resistant because their peptidoglycan is shielded by an outer membrane).

Antimicrobial peptides (AMPs) — defensins and cathelicidins — are small (12–50 amino acid), cationic, amphipathic peptides produced constitutively (and further induced during inflammation) by epithelial cells, Paneth cells of the small intestine, and neutrophils. Their mechanism is physical rather than enzymatic: the peptide's positively charged residues are attracted electrostatically to the negatively charged phospholipid heads and lipopolysaccharide of microbial membranes (mammalian membranes are more neutral, giving selectivity), and the peptide's amphipathic structure then inserts into the lipid bilayer, aggregating into pores or thinning the membrane by a "carpet" mechanism until it ruptures, causing loss of ions, ATP, and cytoplasmic content — cell death within minutes. α-defensins (HD5, HD6) are stored in the granules of intestinal Paneth cells at the base of crypts and released in response to bacterial products, forming a chemical curtain that keeps the small intestinal crypts nearly sterile. β-defensins (hBD-1 to hBD-4) are made by keratinocytes and respiratory/urogenital epithelial cells. Cathelicidin (LL-37) in humans is stored in neutrophil granules and keratinocytes and has the additional property of chemoattracting immune cells, linking the barrier system to the inducible innate response.

Microbiota-mediated colonization resistance. The trillions of commensal bacteria occupying skin, gut, mouth, and vagina are not passive bystanders — they actively exclude pathogens through several concrete mechanisms: (1) niche/nutrient competition, consuming limited carbon sources and adhesion sites so invading species cannot get a foothold; (2) direct antagonism, producing bacteriocins, hydrogen peroxide, and short-chain fatty acids (acetate, propionate, butyrate) that lower local pH and inhibit competitors; (3) immune priming, stimulating epithelial cells and mucosal immune tissue (e.g., inducing mucin and AMP production) so barriers stay primed even in the absence of infection. This is why disrupting the microbiota with broad-spectrum antibiotics predictably allows overgrowth of resistant, often pathogenic organisms such as Clostridioides difficile.

Fleming's discovery of lysozyme (1922). Alexander Fleming — later famous for penicillin — was investigating why nasal mucus seemed to inhibit bacterial growth. In a now-famous anecdote, Fleming added a drop of his own nasal mucus (from a cold) to a bacterial culture plate and observed clearing of the bacteria around the mucus. He isolated the responsible substance, named it lysozyme, and showed it was present in tears, saliva, and mucus, and that it could lyse a harmless soil bacterium (which he called Micrococcus lysodeikticus) by dissolving its cell wall. This was the first demonstration that mucosal secretions contain a defined, isolable antimicrobial enzyme rather than being merely a mechanical barrier — establishing the "chemical barrier" concept experimentally rather than as inference from anatomy. Later biochemical work (X-ray crystallography of lysozyme by David Phillips in the 1960s) identified its precise mechanism: hydrolysis of the β-1,4 bond in peptidoglycan, confirming Fleming's functional observation at the molecular level.

Germ-free (gnotobiotic) animal studies establishing colonization resistance. Beginning in the mid-20th century, researchers (notably at the Lobund Institute, Notre Dame, and later many microbiome laboratories) raised mice in sterile isolators from birth, entirely free of microbiota ("germ-free" or axenic mice). These animals show a striking, reproducible phenotype: an underdeveloped gut-associated lymphoid tissue, thinner mucus layer, reduced Paneth cell antimicrobial peptide output — and, critically, are far more susceptible to experimental infection with pathogens such as Salmonella than conventionally raised mice, often requiring 10- to 10,000-fold lower doses of pathogen to establish infection depending on the organism and study. When a defined microbial community is reintroduced ("gnotobiotic" colonization), resistance to pathogen colonization is restored within days to weeks, and the effect can be transferred by fecal transplantation from resistant donor mice to susceptible germ-free recipients. This directly proved — by manipulation, not correlation — that the microbiota itself, not merely host genetics, causes colonization resistance. A modern, clinically decisive extension of this logic is the treatment of recurrent Clostridioides difficile infection with fecal microbiota transplantation (FMT): randomized and observational studies (e.g., van Nood et al., New England Journal of Medicine, 2013) showed cure rates around 90% with donor-stool infusion versus roughly 30% with vancomycin alone, providing direct clinical evidence that restoring a competitive microbiota re-establishes colonization resistance in humans.

Barrier disruption experiments and natural "experiments." Complementary evidence comes from what happens when a specific barrier is selectively removed. Antibiotic-treated mice (which deplete the microbiota chemically rather than by germ-free rearing) show the same increased susceptibility to Salmonella and C. difficile as germ-free animals, confirming the microbiota's role independent of developmental effects on host immune tissue. In humans, patients with achlorhydria (loss of gastric acid production, whether from disease or acid-suppressing drugs such as proton pump inhibitors) show measurably higher rates of enteric bacterial infection and bacterial overgrowth of the small intestine, directly linking the chemical barrier (gastric pH) to a measurable clinical outcome. Burn patients, who lose large areas of intact skin, are a further natural experiment: infection (commonly by Pseudomonas aeruginosa, Staphylococcus aureus) is the leading cause of death in severe burns, precisely tracking loss of the physical/chemical skin barrier rather than any defect in the burn patient's white blood cells.

Example 1 — Reasoning through an achlorhydria case. A 68-year-old patient has taken a proton pump inhibitor (PPI) for 6 years, raising stomach pH from a normal fasting value of about 1.5–2.5 up to around 4–6. She develops recurrent bouts of bacterial gastroenteritis after meals that previously would not have caused illness, and stool testing reveals small intestinal bacterial overgrowth (SIBO). Reason through the mechanism: gastric acid at pH < 3 kills the great majority of ingested bacteria within minutes by protein denaturation; raising pH to 4–6 removes this chemical barrier, so an infectious dose that would normally be reduced by several orders of magnitude before reaching the small intestine survives largely intact. Because fewer organisms are killed, a smaller ingested inoculum now exceeds the infectious dose threshold, and because acid also normally limits upward migration of colonic-type bacteria into the small bowel, chronic hypochlorhydria additionally permits bacterial overgrowth in a region that should be comparatively sterile. The clinical prediction that follows directly from the mechanism — and is observed in epidemiological studies of PPI users — is an increased risk of Salmonella, Campylobacter, and C. difficile infection, exactly the pattern seen in this patient.

Example 2 — Comparing infection risk after two different physical breaches. Consider two patients: Patient A has a 2-cm surgical incision closed primarily with sutures, and Patient B has a 30% total body surface area (TBSA) partial-thickness burn. Both are exposed to similar environmental bacterial loads. Estimate relative infection risk using barrier logic rather than guesswork. Patient A's breach is small, linear, and rapidly re-sealed by clot formation and re-epithelialization (basal keratinocytes migrate across a incision within roughly 24–48 hours to restore a provisional barrier); the total surface area of exposed dermis is on the order of a few square centimeters, and normal wound care (dressing, antisepsis) further limits microbial access. Patient B has destroyed the stratum corneum, living epidermis, and often superficial dermis over a large fraction of body surface — roughly 0.3 × total skin area (~1.8 m² average adult), i.e. over 5,000 cm² of exposed, moist, protein-rich tissue with no acid mantle, no mucus, and impaired local blood flow limiting delivery of any inducible immune response. The quantitative mismatch in exposed area (a few cm² vs. thousands of cm²) combined with loss of every layer of the physical/chemical barrier at once (mechanical seal, acid pH, AMPs, competing normal flora all removed together) explains why burn size, not organism virulence, is the dominant predictor of sepsis risk in burn units, and why burns over roughly 20–30% TBSA carry a markedly elevated risk of invasive infection and sepsis in clinical series.

Alexander Fleming (1881–1955) trained as a bacteriologist at St. Mary's Hospital Medical School, London, working under Sir Almroth Wright, a pioneer of vaccine therapy. Fleming had a reputation among colleagues for keeping untidy, overgrown culture plates — a habit that, twice in his career, led directly to major discoveries. In 1922, while suffering from a cold, Fleming performed a characteristically casual experiment: he tested whether his own nasal secretions had any effect on bacteria growing on an agar plate, and observed a zone of clearing. Rather than dismissing this as contamination or coincidence, he pursued it systematically, testing tears, saliva, and egg white, and demonstrated that a single soluble enzyme — which he named lysozyme — was responsible, capable of dissolving the cell walls of certain bacteria on contact. Although lysozyme turned out to be a comparatively narrow-spectrum defense (effective mainly against the peptidoglycan of Gram-positive organisms lacking a protective outer membrane), the discovery was conceptually pivotal: it proved that mucosal secretions contain identifiable antimicrobial chemistry, laying groundwork for the entire modern framework of chemical barrier immunity later filled out by defensins, cathelicidins, and lactoferrin. Six years later, the same instinct for following up an "accidental" observation on an untidy plate led Fleming to notice that a Penicillium mold contaminant was inhibiting Staphylococcus growth nearby — the discovery of penicillin, which won him the 1945 Nobel Prize in Physiology or Medicine, shared with Howard Florey and Ernst Chain, who developed it into a usable drug.

Understanding physical and chemical barriers directly shapes clinical practice and public health. Burn and wound care is built entirely around restoring the skin barrier as fast as possible (early debridement, skin grafting, topical antimicrobials) because infection risk tracks barrier loss more tightly than almost any other variable. Cystic fibrosis results in thick, poorly cleared mucus in the airway; because the mucociliary escalator fails, patients suffer chronic bacterial colonization (classically Pseudomonas aeruginosa) and recurrent pneumonia — a direct clinical illustration of what happens when a physical barrier mechanism is genetically broken. Proton pump inhibitor prescribing now carries documented warnings about increased enteric infection risk, a direct translation of the gastric-acid-barrier mechanism into prescribing guidelines. Fecal microbiota transplantation is now a standard, guideline-endorsed treatment for recurrent C. difficile infection, arguably the most direct clinical application of colonization-resistance biology, and research is actively extending the same logic to inflammatory bowel disease and to reducing antibiotic-resistant organism carriage before transplant or chemotherapy. In agriculture, probiotic and prebiotic feed additives are used in livestock to bolster gut colonization resistance and reduce reliance on growth-promoting antibiotics. In dermatology and cosmetics, "skin barrier" and "microbiome-friendly" product design (avoiding disruption of the acid mantle and resident skin flora) is now directly informed by this same immunology. Finally, engineered antimicrobial peptides derived from natural defensins and cathelicidins are in development as a new class of antibiotics, precisely because their membrane-disruption mechanism is harder for bacteria to evolve resistance against than most conventional, enzyme-targeted antibiotics — connecting this foundational barrier biology to the frontier of the antibiotic resistance crisis. These same barrier concepts set up the next layer of defense, the inducible innate response covered under Inflammation: The Innate Response to Tissue Damage and The Acute-Phase Response, which activate only once a barrier has actually been breached.

Ask the tutor: How do antimicrobial peptides distinguish microbial membranes from the host's own cells so precisely, and could that selectivity be engineered into new antibiotics?